- Home
- JANX vs HTD Comparison
JANX vs HTD Comparison
Compare JANX & HTD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JANX | HTD |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.3M | 896.4M |
| IPO Year | 2021 | 2003 |
Fundamental Metrics
Financial Performance| Metric | JANX | HTD |
|---|---|---|
| Price | $13.76 | $24.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $53.60 | N/A |
| AVG Volume (30 Days) | ★ 759.1K | 54.7K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.12 | $20.31 |
| 52 Week High | $35.34 | $26.12 |
Technical Indicators
Market Signals| Indicator | JANX | HTD |
|---|---|---|
| Relative Strength Index (RSI) | 49.58 | 47.62 |
| Support Level | $13.80 | $24.30 |
| Resistance Level | $14.44 | $25.21 |
| Average True Range (ATR) | 0.51 | 0.33 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 39.09 | 47.95 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.